Trends and Black/White Differences in Treatment for Nonmetastatic Prostate Cancer

Medical Care

Volumn 36, Issue 9, 1998, Pages 1337-1348

  Klabunde, Carrie N ^a   Potosky, Arnold L ^a   Harlan, Linda C ^a   Kramer, Barnett S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Comorbidity; Practice variation; Prostate cancer; Race; Socioeconomic status; Treatment

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; CANCER STAGING; CAUCASIAN; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CULTURAL FACTOR; ETHNOLOGY; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; NEGRO; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; RADIOTHERAPY; SOCIOECONOMICS; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMBINED MODALITY THERAPY; CROSS-CULTURAL COMPARISON; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 0032158513     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199809000-00006     Document Type: Article

References (56)

1. Wingo PA, Landis S, Ries LAG. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 1997;47:239.
2. National Cancer Institute. Cancer rates and risks. Bethesda, MD: Division of Cancer Prevention and Control: Cancer Statistics Branch, 1996.
3. Merrill RM, Potosky AL, Feuer EJ. Changing trends in US prostate cancer incidence rates. J Natl Cancer Inst 1996;88:1683.
4. Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A, Edwards BK, eds. Cancer statistics review, 1973-1992: Tables and graphs. Bethesda, MD: National Cancer Institute. NIH Publication No. 96-2789, 1995.
5. Albertsen PC. African-Americans and prostate cancer. The Cancer Journal from Scientific American 1996;2:200.
6. National Cancer Institute. Racial/ethnic patterns of cancer in the United States, 1988-1992. Bethesda, MD: National Institutes of Health, NIH Publication Number 96-4104, 1996.
7. National Institutes of Health Consensus Development Panel. Consensus statement: The management of clinically localized prostate cancer. NCI Monographs 1988;7:3.
8. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Arch Fam Med 1993;2:487.
9. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242.
10. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626.
11. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden. JAMA 1997;277:467.
12. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet 1997;349:906.
13. Whitmore WF. Management of clinically localized prostatic cancer: An unresolved problem. JAMA 1993;269:2676.
14. Fowler FJ, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy: The national Medicare experience, 1988-1990. Urology 1993;42:622.
15. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129.
16. Fowler FJ, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: A study of Medicare beneficiaries in three Surveillance, Epidemiology, and End Results areas. J Clin Oncol 1996;14:2258.
17. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy: Time trends, geographic variation, and outcomes. JAMA 1993;269:2633.
18. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 1995;13:93.
19. Schapira MM, McAuliffe TL, Nattinger AB. Treatment of localized prostate cancer in African-American compared with Caucasian men: Less use of aggressive therapy for comparable disease. Med Care 1995;33:1079.
20. Bennett CL, Greenfield S, Aronow H, Ganz P, Vogelzang NJ, Elashoff RM. Patterns of care related to age of men with prostate cancer. Cancer 1991;67:2633.
21. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care 1996;34:152.
22. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1991 update: 3. Secondary prevention of prostate cancer. Can Med Assoc J 1991;145:413.
23. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: What we know and what we need to know. Ann Intern Med 1993;119:914.
24. US Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore, MD: Williams & Wilkins, 1996.
25. Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment, and costs of prostate cancer in England and Wales. Health Technol Assess 1997;1:19.
26. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management, and screening of early localised prostate cancer. Health Technol Assess 1997;1:11.
27. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156.
28. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974-1990: Observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin 1993;43:83.
29. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548.
30. Potosky AL, Riley GF, Lubitz JD, Mentnech RM Kessler LG. Potential for cancer-related health services research using a linked Medicare tumor registry database. Med Care 1993;31:732.
31. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613.
32. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40:373.
33. Lane PW, Neider JA. Analysis of covariance and standardization as instances of prediction. Biometrics 1982;38:613.
34. Ries L, Kosary C. Stat bite: Prostate cancer incidence, 1973-1994. J Natl Cancer Inst 1997;89:609.
35. McWhorter WP, Mayer WJ. Black/white differences in type of initial breast cancer treatment and implications for survival. Am J Public Health 1987;77:1515.
36. Goldberg KC, Hartz AJ, Jacobsen SJ, Krakauer H, Rimm AA. Racial and community factors influencing coronary artery bypass graft surgery rates for all 1986 Medicare patients. JAMA 1992;267:1473.
37. Ball JK, Elixhauser A. Treatment differences between blacks and whites with colorectal cancer. Med Care 1996;34:970.
38. Cooper GS, Yuan Z, Landefeld CS, Rimm AA. Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries. Am J Public Health 1996;86:582.
39. Escarce JJ, Epstein KR, Colby DC, Schwartz JS. Racial differences in the elderly's use of medical procedures and diagnostic tests. Am J Public Health 1993;83:948.
40. McBean AM, Gornick M. Differences by race in the rates of procedures performed in hospitals for Medicare beneficiaries. Health Care Financing Rev 1994;15:77.
41. Gornick ME, Eggers PW, Reilly TW, et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N Engl J Med 1996;335:791.
42. Wenneker MB, Epstein AM. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts. JAMA 1989;261:253.
43. Udvarhelyi IS, Gatsonis C, Epstein AM, Pashos CL, Newhouse JP, McNeil BJ. Acute myocardial infarction in the Medicare population: Process of care and clinical outcomes. JAMA 1992;268:2530.
44. Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial differences in the use of invasive cardiovascular procedures in the Department of Veterans Affairs medical system. N Engl J Med 1993;329:621.
45. Sheldon CA, Williams RD, Fraley EE. Incidental carcinoma of the prostate: A review of the literature and critical appraisal of classification. J Urol 1980;124:626.
46. Rohr LR. Incidental adenocarcinoma in transurethral resections of the prostate: Partial versus complete microscopic examination. Am J Surg Pathol 1987;11:53.
47. Ramon J, Rossignol G, Leandri P, Gautier JR. Morbidity of radical retropubic prostatectomy following previous prostate resection. J Surg Oncol 1994;55:14.
48. Arcangeli G, Micheli A, Verna L, et al. Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. Radiother Oncol 1995;35:123.
49. Mansfield JT, Stephenson RA. Does transurethral resection of the prostate compromise the radical treatment of prostate cancer? Semin Urol Oncol 1996;14:174.
50. Greenberg ER, Chute CG, Stukel T, et al. Social and economic factors in the choice of lung cancer treatment: A population-based study in two rural states. N Engl J Med 1988;318:612.
51. Optenberg SA, Thompson IM, Friedrichs P, Wojcik B, Stein CR, Kramer B. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 1995;274:1599.
52. Wennberg JE, Gittelsohn A. Small area variations in health care delivery. Science 1973;182:1102.
53. Eisenberg JM. Doctors' decisions and the cost of medical care. Ann Arbor, MI: Health Administration Press Perspectives, 1986.
54. Gerrity MS, Devellis RE, Earp J. Physicians' reactions to uncertainty in patient care: A new measure and new insights. Med Care 1990;28:724.
55. Gohagan JK, Kramer BS, Greenwald P. Screening for prostate cancer. Am J Prev Med 1994;10:245.
56. Moon TD, Brawer MK, Wilt TJ. Prostate Intervention Versus Observation Trial (PIVOT): A randomized trial comparing radical prostatectomy with palliative expectant management for treatment of clinically localized prostate cancer. J Natl Cancer Inst Monogr 1995; 19:69.